ADAPTIVE BIOTECHNOLOGIES CORPORATION Revenue
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Revenue of $71.55 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $71.55M, a 21.53% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $70.87M, a 35.14% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $71.68M, a 51.04% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $93.97M, a 102.38% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2025 was $276.98M, a 54.77% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2024 was $178.96M, a 5.10% increase from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2023 was $170.28M, a 8.11% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION revenue from contract with customer, excluding assessed tax for fiscal 2022 was $185.31M, a 20.06% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $71.55M 10-Q · filed 2026-08-04 | $142.43M 10-Q · filed 2026-08-04 | $214.11M derived: sum of 3 quarters · filed 2026-08-04 | $308.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $70.87M 10-Q · filed 2026-05-05 | $142.56M derived: sum of 2 quarters · filed 2026-05-05 | $236.53M derived: sum of 3 quarters · filed 2026-05-05 | $295.41M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $71.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $165.65M derived: sum of 2 quarters · filed 2026-02-26 | $224.53M derived: sum of 3 quarters · filed 2026-08-04 | $276.98M 10-K · filed 2026-02-26 |
| 2025-09-30 | $93.97M 10-Q · filed 2025-11-05 | $152.85M derived: sum of 2 quarters · filed 2026-08-04 | $205.29M 10-Q · filed 2025-11-05 | $252.75M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $58.88M 10-Q · filed 2026-08-04 | $111.32M 10-Q · filed 2026-08-04 | $158.78M derived: sum of 3 quarters · filed 2026-08-04 | $205.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $52.44M 10-Q · filed 2026-05-05 | $99.90M derived: sum of 2 quarters · filed 2026-05-05 | $146.34M derived: sum of 3 quarters · filed 2026-05-05 | $189.53M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $47.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $93.89M derived: sum of 2 quarters · filed 2026-02-26 | $137.08M derived: sum of 3 quarters · filed 2026-02-26 | $178.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | $46.44M 10-Q · filed 2025-11-05 | $89.63M derived: sum of 2 quarters · filed 2025-11-05 | $131.50M 10-Q · filed 2025-11-05 | $177.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $43.19M 10-Q · filed 2025-08-05 | $85.06M 10-Q · filed 2025-08-05 | $130.85M derived: sum of 3 quarters · filed 2026-02-26 | $168.77M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $41.87M 10-Q · filed 2025-05-01 | $87.66M derived: sum of 2 quarters · filed 2026-02-26 | $125.58M derived: sum of 3 quarters · filed 2026-02-26 | $174.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $45.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $83.70M derived: sum of 2 quarters · filed 2026-02-26 | $132.63M derived: sum of 3 quarters · filed 2026-02-26 | $170.28M 10-K · filed 2026-02-26 |
| 2023-09-30 | $37.92M 10-Q · filed 2024-11-07 | $86.84M derived: sum of 2 quarters · filed 2024-11-07 | $124.49M 10-Q · filed 2024-11-07 | $179.69M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $48.93M 10-Q · filed 2024-08-01 | $86.57M 10-Q · filed 2024-08-01 | $141.77M derived: sum of 3 quarters · filed 2025-03-03 | $189.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $37.65M 10-Q · filed 2024-05-07 | $92.84M derived: sum of 2 quarters · filed 2025-03-03 | $140.68M derived: sum of 3 quarters · filed 2025-03-03 | $184.34M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $55.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $103.03M derived: sum of 2 quarters · filed 2025-03-03 | $146.69M derived: sum of 3 quarters · filed 2025-03-03 | $185.31M 10-K · filed 2025-03-03 |
| 2022-09-30 | $47.83M 10-Q · filed 2023-11-09 | $91.49M derived: sum of 2 quarters · filed 2023-11-09 | $130.11M 10-Q · filed 2023-11-09 | $168.04M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $43.66M 10-Q · filed 2023-08-02 | $82.28M 10-Q · filed 2023-08-02 | $120.21M derived: sum of 3 quarters · filed 2024-02-29 | $159.68M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $38.62M 10-Q · filed 2023-05-03 | $76.55M derived: sum of 2 quarters · filed 2024-02-29 | $116.02M derived: sum of 3 quarters · filed 2024-02-29 | $154.52M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $37.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $77.40M derived: sum of 2 quarters · filed 2024-02-29 | $115.90M derived: sum of 3 quarters · filed 2024-02-29 | $154.34M 10-K · filed 2024-02-29 |
| 2021-09-30 | $39.47M 10-Q · filed 2022-11-03 | $77.97M derived: sum of 2 quarters · filed 2022-11-03 | $116.41M 10-Q · filed 2022-11-03 | $146.60M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $38.51M 10-Q · filed 2022-08-03 | $76.95M 10-Q · filed 2022-08-03 | $107.13M derived: sum of 3 quarters · filed 2023-02-14 | $133.43M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $38.44M 10-Q · filed 2022-05-04 | $68.63M derived: sum of 2 quarters · filed 2023-02-14 | $94.93M derived: sum of 3 quarters · filed 2023-02-14 | $115.91M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $30.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $56.48M derived: sum of 2 quarters · filed 2023-02-14 | $77.47M derived: sum of 3 quarters · filed 2023-02-14 | $98.38M 10-K · filed 2023-02-14 |
| 2020-09-30 | $26.30M 10-Q · filed 2021-11-03 | $47.29M derived: sum of 2 quarters · filed 2021-11-03 | $68.20M 10-Q · filed 2021-11-03 | $92.41M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $20.99M 10-Q · filed 2021-08-04 | $41.90M 10-Q · filed 2021-08-04 | $66.11M derived: sum of 3 quarters · filed 2022-02-15 | $92.17M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $20.91M 10-Q · filed 2021-05-05 | $45.12M derived: sum of 2 quarters · filed 2022-02-15 | $71.18M derived: sum of 3 quarters · filed 2022-02-15 | $93.31M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $24.21M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $50.27M derived: sum of 2 quarters · filed 2022-02-15 | $72.41M derived: sum of 3 quarters · filed 2022-02-15 | $85.07M 10-K · filed 2022-02-15 |
| 2019-09-30 | $26.06M 10-Q · filed 2020-11-10 | $48.20M derived: sum of 2 quarters · filed 2020-11-10 | $60.86M 10-Q · filed 2020-11-10 | $78.05M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $22.14M 10-Q · filed 2020-08-10 | $34.80M 10-Q · filed 2020-08-10 | $52.00M derived: sum of 3 quarters · filed 2021-02-24 | $69.18M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $12.67M 10-Q · filed 2020-05-12 | $29.86M derived: sum of 2 quarters · filed 2021-02-24 | $47.05M derived: sum of 3 quarters · filed 2021-02-24 | $58.61M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $17.19M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $34.38M derived: sum of 2 quarters · filed 2021-02-24 | $45.95M derived: sum of 3 quarters · filed 2021-02-24 | $55.66M 10-K · filed 2021-02-24 |
| 2018-09-30 | $17.19M 10-Q · filed 2019-11-12 | $28.76M derived: sum of 2 quarters · filed 2019-11-12 | $38.47M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $11.57M 10-Q · filed 2019-08-13 | $21.28M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $38.45M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |